METABOLIC DYSFUNCTION– ASSOCIATED STEATOTIC LIVER DISEASE IS ASSOCIATED WITH HIGHER MORTALITY AND HEPATIC DECOMPENSATION IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A PROPENSITY-MATCHED ANALYSIS OF A FEDERATED HEALTH NETWORK (AASLD 2026) - Oct 6, 2026 - Abstract #4282; Pres time: Nov 8, 2026; 01:00 PM - 02:00 PM; Location: Convention Center: Poster Hall, Hall DE; "Adults with HCC who initiated an ICI (atezolizumab, durvalumab, tremelimumab, nivolumab, pembrolizumab, or ipilimumab) after HCC diagnosis were identified. In this large, propensitymatched real-world cohort, MASLD-HCC patients treated with ICIs had significantly higher mortality and more frequent, earlier hepatic decompensation than non-MASLD HCC patients. These findings support the hypothesis that the MASLD immunometabolic milieu limits ICI efficacy and underscore the need for etiologyspecific strategies, including microbiome-targeted approaches."
Checkpoint inhibition • Clinical • Cardiovascular • CNS Disorders • Gastroenterology • Hematological Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Oncology • Renal Disease • Solid Tumor • Thrombosis
|
|
Mazen Elsheikh1; Osamah Salim2; Hamza Salim3; Sherry Fares1; Karim Adhem1; Mohamad Ali Ibrahim1; Youseph Karouni1; Nicholas Thomas1; Krishna Chandrasekhara1; Prasun Jalal1
|